Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWTCR001 in advanced solid tumors
NCT06170294Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JWTCR001 in solid tumor (advanced stage), sponsored by Peking University. Primary endpoints: Rate of dose-limiting toxicities at 28 days, Rate and severity of adverse events at 2 years and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
JWTCR001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06170294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170294.